Company: ABUS
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001140361-25-012305
Chunk: 15

Company: Arbutus Biopharma Corp
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 15
---
 outcome of the vote when considering executive compensation decisions for our executive officers going forward. As a result of our last “say-on-frequency” vote, which occurred at the 2021 Annual General and Special Meeting, we will hold this advisory “say-on-pay” vote annually. Our executive compensation program is designed to attract and motivate our executive officers. This vote on the compensation of our named executive officers, all of whom have departed the Company, is required by SEC rules and will be used to inform future compensation decisions for our executive officers. We encourage our Shareholders to read the “ Summary Compensation Table” and other related compensation tables and narrative disclosures in the “ Executive Compensation” section of this Proxy Statement/Circular, which describe the 2024 compensation of our named executive officers, all of whom have departed the Company. We are asking our Shareholders to approve, on an advisory basis, the compensation of our named executive officers, all of whom have departed the Company, as disclosed in this Proxy Statement/Circular pursuant to Item 402 of Regulation S-K, including the compensation tables and the narrative disclosures that accompany the compensation tables. Vote Required and Recommendation of our Board The approval of this Proposal No. 2 requires a majority of the votes cast at the Annual Meeting. For purposes of determining the number of votes cast, only the Common Shares voting “FOR” or “AGAINST” will be counted. Because this is an advisory vote, there is no minimum approval necessary; however, our Board will consider the results of this advisory vote when considering future decisions related to such proposal. Our Board recommends that our Shareholders vote FOR Proposal No. 2 to approve the compensation of the Company’s named executive officers. 8 TABLE OF CONTENTS PROPOSAL NO. 3 – APPROVAL OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM The Audit Committee has reappointed, subject to Shareholder approval, EY to serve as our independent registered public accounting firm and to audit our financial statements for the fiscal year ending December 31, 2025. Management requests that our Shareholders approve the appointment of EY. If the appointment of EY is not approved by the Shareholders, EY shall continue to serve as our independent registered public accounting firm until a successor is appointed. EY was our independent registered public accounting firm for the fiscal year ended December 31, 2024. EY is expected to have a representative attend the Annual Meeting to be available to respond to appropriate questions and to make a statement if he or she